Market Closed -
Nasdaq
04:00:00 2024-04-30 pm EDT
|
5-day change
|
1st Jan Change
|
33.62
USD
|
-3.00%
|
|
-5.85%
|
+32.05%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,748
|
3,259
|
1,369
|
1,413
|
2,063
|
-
|
-
|
Enterprise Value (EV)
1 |
2,453
|
2,819
|
809.9
|
976.4
|
1,547
|
1,600
|
1,514
|
P/E ratio
|
-19.7
x
|
-30.4
x
|
-8.7
x
|
-10.1
x
|
-10.4
x
|
-9.55
x
|
-9.44
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.7
x
|
44.7
x
|
29.2
x
|
18
x
|
39
x
|
30.6
x
|
26.7
x
|
EV / Revenue
|
72.1
x
|
38.7
x
|
17.3
x
|
12.4
x
|
29.2
x
|
23.7
x
|
19.6
x
|
EV / EBITDA
|
-55.1
x
|
-28.7
x
|
-5.12
x
|
-6.03
x
|
-7.74
x
|
-9.76
x
|
-9.03
x
|
EV / FCF
|
31
x
|
-21.6
x
|
-5.19
x
|
-7.11
x
|
-8.6
x
|
-8.46
x
|
-7.89
x
|
FCF Yield
|
3.22%
|
-4.63%
|
-19.3%
|
-14.1%
|
-11.6%
|
-11.8%
|
-12.7%
|
Price to Book
|
9.72
x
|
7.12
x
|
2.75
x
|
3.58
x
|
4.08
x
|
4.51
x
|
5.15
x
|
Nbr of stocks (in thousands)
|
44,326
|
51,332
|
54,865
|
55,487
|
61,358
|
-
|
-
|
Reference price
2 |
62.00
|
63.49
|
24.96
|
25.46
|
33.62
|
33.62
|
33.62
|
Announcement Date
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.934
|
34.03
|
72.83
|
46.83
|
78.59
|
52.9
|
67.47
|
77.18
|
EBITDA
1 |
-
|
-44.54
|
-98.13
|
-158.3
|
-162
|
-199.9
|
-164
|
-167.8
|
EBIT
1 |
-
|
-46.3
|
-100.5
|
-161.3
|
-165.5
|
-227.9
|
-253.7
|
-259.1
|
Operating Margin
|
-
|
-136.05%
|
-138.03%
|
-344.37%
|
-210.62%
|
-430.88%
|
-376.08%
|
-335.74%
|
Earnings before Tax (EBT)
1 |
-
|
-45.59
|
-100.2
|
-154.8
|
-147
|
-216.7
|
-264.8
|
-286.1
|
Net income
1 |
-
|
-54.64
|
-100.2
|
-154.8
|
-147
|
-217.7
|
-252
|
-265.8
|
Net margin
|
-
|
-160.55%
|
-137.6%
|
-330.6%
|
-186.99%
|
-411.59%
|
-373.47%
|
-344.36%
|
EPS
2 |
-
|
-3.150
|
-2.090
|
-2.870
|
-2.520
|
-3.234
|
-3.520
|
-3.563
|
Free Cash Flow
1 |
-
|
79.03
|
-130.5
|
-155.9
|
-137.3
|
-179.8
|
-189.1
|
-192
|
FCF margin
|
-
|
232.22%
|
-179.24%
|
-332.98%
|
-174.71%
|
-339.81%
|
-280.24%
|
-248.77%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/31/20
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
20.34
|
15.28
|
9.622
|
11.51
|
9.551
|
16.14
|
9.466
|
16.51
|
4.728
|
47.88
|
13.05
|
11.21
|
9.518
|
13.13
|
22.85
|
EBITDA
1 |
-27.97
|
-33.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-18.42
|
-50.69
|
-49.1
|
-64.64
|
-
|
-
|
EBIT
1 |
-28.64
|
-33.99
|
-36.93
|
-40.81
|
-44.88
|
-38.63
|
-45.33
|
-43.38
|
-57.51
|
-19.31
|
-53.2
|
-56.44
|
-60.58
|
-58.32
|
-57.02
|
Operating Margin
|
-140.82%
|
-222.55%
|
-383.84%
|
-354.44%
|
-469.92%
|
-239.36%
|
-478.83%
|
-262.72%
|
-1,216.35%
|
-40.33%
|
-407.51%
|
-503.49%
|
-636.53%
|
-444.15%
|
-249.58%
|
Earnings before Tax (EBT)
1 |
-28.58
|
-33.9
|
-36.68
|
-40.26
|
-43
|
-34.86
|
-40.93
|
-38.8
|
-52.87
|
-14.37
|
-47.17
|
-52.11
|
-57.41
|
-55.06
|
-73.5
|
Net income
1 |
-28.58
|
-33.9
|
-36.68
|
-40.26
|
-43
|
-34.86
|
-40.93
|
-38.8
|
-52.87
|
-14.37
|
-48.46
|
-52.6
|
-57.1
|
-56.55
|
-73.5
|
Net margin
|
-140.55%
|
-221.93%
|
-381.25%
|
-349.64%
|
-450.24%
|
-216.03%
|
-432.37%
|
-234.96%
|
-1,118.17%
|
-30.01%
|
-371.19%
|
-469.21%
|
-599.91%
|
-430.67%
|
-321.72%
|
EPS
2 |
-0.5600
|
-0.6700
|
-0.7100
|
-0.7800
|
-0.7900
|
-0.5900
|
-0.7000
|
-0.6700
|
-0.9000
|
-0.2500
|
-0.7274
|
-0.7713
|
-0.8239
|
-0.8046
|
-0.8094
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
2/24/22
|
5/3/22
|
8/9/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
295
|
440
|
559
|
436
|
516
|
463
|
549
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
79
|
-131
|
-156
|
-137
|
-180
|
-189
|
-192
|
ROE (net income / shareholders' equity)
|
-
|
-52.2%
|
-27%
|
-32.6%
|
-33.2%
|
-36.9%
|
-40.3%
|
-60.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-18.3%
|
-25.6%
|
-24.9%
|
-27.3%
|
-33.9%
|
-43.1%
|
Assets
1 |
-
|
-
|
546.5
|
604.5
|
589.4
|
799
|
743.3
|
617.4
|
Book Value Per Share
2 |
-
|
6.380
|
8.920
|
9.090
|
7.110
|
8.230
|
7.460
|
6.530
|
Cash Flow per Share
2 |
-
|
5.080
|
-2.690
|
-2.840
|
-1.760
|
1.050
|
-3.650
|
-2.320
|
Capex
1 |
-
|
9.1
|
1.6
|
2.84
|
34.5
|
7.28
|
6.37
|
5.98
|
Capex / Sales
|
-
|
26.73%
|
2.19%
|
6.06%
|
43.87%
|
13.77%
|
9.45%
|
7.75%
|
Announcement Date
|
7/31/20
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
34.66
USD Average target price
51.07
USD Spread / Average Target +47.34% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.05% | 2.13B | | +0.17% | 42.86B | | +10.92% | 42.74B | | +44.30% | 41.36B | | -6.20% | 27.68B | | +5.23% | 25.15B | | -24.79% | 18.63B | | +26.69% | 12.37B | | -3.13% | 11.92B | | +6.57% | 11.21B |
Other Biotechnology & Medical Research
|